Dengue vaccine: Priorities and progress

Expert Review of Anti-Infective Therapy

Volumn 2, Issue 6, 2004, Pages 895-911

  Guzmán, María G ^a   Muné, Mayra ^a   Kourí, Gustavo ^a  

^a INSTITUTO DE MEDICINA TROPICAL PEDRO KOURÍ   (Cuba)

Author keywords

Attenuated; Chimeric; Clinical trials; Dengue; Dengue hemorrhagic fever; Recombinant; Vaccine

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; DENGUE VACCINE; DNA VACCINE; DRUG CARRIER; LIVE VACCINE; M PROTEIN; NEUTRALIZING ANTIBODY; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR;

ANIMAL MODEL; CLINICAL TRIAL; DENGUE; DENGUE VIRUS; DISEASE MODEL; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; ESCHERICHIA COLI; EYE PAIN; FEVER; FINANCIAL MANAGEMENT; HEADACHE; HUMAN; IMMUNE RESPONSE; INSECT CONTROL; MALAISE; MEDICAL RESEARCH; MONKEY; MOSQUITO; MOUSE; MYALGIA; NEISSERIA MENINGITIDIS; NEUTROPENIA; NONHUMAN; PASSIVE IMMUNIZATION; POXVIRUS; PROPHYLAXIS; PRURITUS; REVIEW; SEROCONVERSION; T LYMPHOCYTE ACTIVATION; TERATOGENICITY; THROMBOCYTOPENIA; TREATMENT OUTCOME; VACCINIA VIRUS; VIRUS REPLICATION; VIRUS TRANSMISSION; VIRUS VIRULENCE;

EID: 9944225585     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14789072.2.6.895     Document Type: Review

References (198)

1. Smolinski MS, Hamburg MA, Lederberg J (Eds). Microbial Threats to Health: Emergence, Detection and Response. The National Academies Press, WA, USA (2003).
2. Gubler DJ. The changing epidemiology of yellow fever and dengue, 1900 to 2003: full circle? Canadian Institute Microbiol. Infect. Dis. 27, 319-330 (2004).
3. Guzman MG, Kouri G. Dengue - an update. Lancet Infect. Dis. 2, 33-42 (2002).
4. Marfin AA, Gubler DJ. West Nile encephalitis: an emerging disease. Clin. Infect. Dis. 33, 1713-1719 (2001).
5. Rawlins SC. Emerging and re-emerging vector-borne diseases in the Caribbean region. W. Indian Med. J. 48(4), 252-253 (1999).
6. Halstead SB. Dengue in the health transition. Kaohsiung J. Med. Sci. 10, S2-S14 (1994).
7. World Health Organization. Strengthening implementation of the global strategy for dengue fever/dengue hemorrhagic fever prevention and control. Report of the informal consultation, World Health Organization, Geneva 18-20 October 1999.
8. Guzman MG, Kouri G. Dengue and dengue hemorrhagic fever in the Americas: lessons and challenges. J. Clin. Virol. 27, 1-13 (2003).
9. Gubler DJ. Dengue and dengue hemorrhagic fever: its history and resurgence as a global public health problem. In: Dengue and Dengue Hemorrhagic Fever. Gubler DJ, Kuno G (Eds). CAB International, London, UK, 1-22 (1997).
10. Pan American Health Organization. Dengue and Dengue Hemorrhagic Fever in the Americas: Guidelines for Prevention and Control Pan American Health Organization Scientific Publication, WA, USA, 548 (1994).
11. Chambers TJ, Hahn CS, Galler R, Rice CM. Flavivirus genome organization, expression and replication. Ann. Rev. Microbiol. 44, 649-688 (1990).
12. Westaway EG, Brinton MA, Gaidamovich SY et al. Flaviviridae. Intervirology 74, 183-192 (1985).
13. Rice CM, Lenches EM, Eddy SR, Shin SJ, Sheets RL, Strauss JH. Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. Science 229, 726-733 (1985).
14. Ashburh PM, Craig CF. Experimental investigations regarding the etiology of dengue fever with general consideration of the disease. Philippine J. Sci. 2, 93-152 (1907).
15. Nimmannitya S. Clinical manifestations of dengue/dengue hemorrhagic fever. Monograph on dengue/dengue hemorrhagic fever. World Health Organization, regional office for Southeast Asia, New Delhi, India 22 (1993).
16. Diaz A, Kouri G, Guzman MG et al. Description of the clinical picture of dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS) in adults. Bull. Pan Am. Health Organ. 22, 133-144 (1988).
17. Guzman MG, Alvarez M, Rodriguez R et al. Fatal dengue hemorrhagic fever in Cuba, 1997. Int. J. Infect. Dis. 3, 130-135 (1999).
18. Pelaez O, Guzman MG, Kouri G et al. Dengue 3 epidemic, Havana, 2001. Emerging Infect. Dis. 10, 719-722 (2004).
19. Harris E, Videa E, Perez L et al. Clinical, epidemiologic and virologic features of dengue in the 1998 epidemic in Nicaragua. Am. J. Trop. Med. Hyg. 63, 5-11 (2000).
20. Kalayanarooj S, Vaughn DW, Nimmannitya S et al. Early clinical and laboratory indicators of acute dengue illness. J. Infect. Dis. 176, 313-321 (1997).
21. Halstead SB, Deen J. The future of dengue vaccines. Lancet 360, 1243-1245 (2002).
22. Kinney RM, Huang CYH. Development of new vaccines against dengue fever and Japanese encephalitis. Intervirology 44, 176-197 (2001).
23. Sabin AB. Research on dengue during World War II. Am. J. Trop. Med. Hyg. 1, 30-50 (1952).
24. Bhamarapravati N, Yoksan S. Live attenuated tetravalent dengue vaccine. In: Dengue and Dengue Hemorrhagic Fever. Gubler DJ, Kuno G (Eds). CAB International, London, UK, 367-377 (1997).
25. Halstead SB. Selective primary healthcare: strategies for control of disease in the developing world. XI Dengue. Rev. Infect. Dis. 6, 251-264 (1984).
26. Von Allmen SD, Lopez-Correa RH, Woodall JP, Morens DM, Chiriboga J, Casta-Velez A. Epidemic dengue fever in Puerto Rico, 1977: a cost analysis. Am. J. Trop. Med. Hyg. 28, 1040-1044 (1979).
27. Guzman MG, Kouri G, Bravo J, Triana C. Estimacion de las afectaciones economicas causadas como consecuencia de la epidemia de dengue hemorragico ocurrida en Cuba en 1981. Rev. Cubana Med. Trop. 44, 13-17 (1992).
28. Valdes L, Vila J, Guzman MG. Impacto economico de la epidemia de dengue 2 en Santiago de Cuba, 1997. Rev. Cubana Med. Trop. 54, 220-227 (2002).
29. Almond J, Clemens J, Engers H et al. Accelerating the development and introduction of a dengue vaccine for poor children, 5-8 December 2001, Ho Chi Minh City, Vietnam. Vaccine 20, 3043-3046 (2002).
30. Melzert MI, Rigau JG, Clark GG, Reiter P, Gubler DJ. Using disability adjusted life years to assess the economic impact of dengue in Puerto Rico: 1984-1994. Am. J. Trop. Med. Hyg. 59, 265-271 (1998).
31. Rigau JG, Clark G, Gubler DJ, Sanders EJ, Vorndam AV. Dengue and dengue hemorrhagic fever. Lancet 352, 971-977 (1998).
32. World Health Organization. Key Issues in Dengue Vector Control Toward the Operationalization of a Global Strategy. World Health Organization, Geneva, Switzerland, 6-10 June 1995.
33. San Martin JL, Prado M. Risk perception and strategies for mass communication on dengue in the Americas. Rev. Pan Am. Salud. Pub. 15, 135-139 (2004).
34. Kroeger A, Nathan M, Hombach J, TDR reference group. Dengue. Nature Rev. Microbiol. 2, 360-361 (2004).
35. World Heald, Organization/Pan American Health Organization. DengueNet implementation in the Americas. Report of a WHO/PAHO/CDC Meeting. WHO/CDS/CSR/GAR/2003.8 San Juan, Puerto Rico, 9-11 July 2002.
36. Pan American Health Organization. New generation of dengue prevention and control programs. Program of communicable diseases. Division of Disease Prevention and control. Pan American Health Organization, WA, USA PAHO/HCP/HCT/224/02 (1999).
37. World Health Organization. Scientific Working Group on Dengue. Meeting report TDR/DEN/SWG/00.1 Geneva, Switzerland, 3-5 April 2000.
38. Putnak R. Progress in the development of recombinant vaccines against dengue and other arthropod-borne flaviviruses. In: Modern Viccinology. Kurstak E (Ed.). Plenum Medical, NY, USA, 231-252 (1994 ).
39. Sabin AB, Schlesinger RW. Production of immunity to dengue with virus modified by propagation in mice. Science 101, 640-642 (1945).
40. Kimura R, Hotta S. Studies on dengue: antidengue active immunization experiments in mice. Japan. J. Bacteriol. 1, 96-99 (1944).
41. Hammon MW, Rudnick A, Sather GE. Viruses associated with epidemic hemorrhagic fever of the Phillippines and Thailand. Science 131, 1102-1103 (1960).
42. Halstead SB, Nimmannitya S, Cohen SN. Observations related to pathogenesis of dengue hemorrhagic fever IV. Relation to disease severity to antibody response and virus recovered. Yale J. Biol. Med. 42, 311-328 (1970).
43. Halstead SB, Scanlon JE, Umpaivit P, Udomsakdi S. Dengue and chikungunya virus infection in man in Thailand, 1962-1964. Am. J. Trop. Med. Hyg. 18, 997-1021 (1969).
44. Halstead SB. Pathogenesis of dengue. Challenge to molecular biology. Science 239, 476-481 (1988).
45. Kliks SC, Nisalak A, Brandt WE, Wahl L, Burke DS. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am. J. Trop. Med. Hyg. 40, 444-451 (1989).
46. Kurane I, Mady BJ, Ennis FA. Antibody-dependent enhancement of dengue virus infection. Rev. Med. Virol. 1, 211-221 (1991).
47. Mathew A, Kurane I, Green S et al. Predominance of CTL responses to serotype crossreactive epitopes on nonstructural protein following natural secondary dengue virus infection. J. Virol. 72, 3999-4004 (1998).
48. Kurane I, Ennis FA. Cytokines and dengue virus infection. Semin. Virol. 5, 443-448 (1994).
49. Lei HY, Yeh TM, Liu HS, Lin YS, Chen SH, Liu CC. Immunopathogenesis of dengue virus infection. J. Biomed. Sci. 8, 377-388 (2001).
50. Green S, Vaughn DW, Kalayanarooj S et al. Early immune activation in acute dengue illness is related to development of plasma leakage and disease severity. J. Infect. Dis. 179, 755-762 (1999).
51. Green S, Pichyangkul S, Vaugn DW et al. Early CD69 expression of peripheral blood lymphocytes from children with dengue hemorrhagic fever. J. Infect. Dis. 180, 1429-1435 (1999).
52. Kurane I, Takasaki T. Dengue fever and dengue hemorrhagic fever: challenges of controlling an enemy still at large. Rev. Med. Virol. 11, 301-311 (2001).
53. Rothman AL, Ennis FA. Immunopathogenesis of dengue hemorrhagic fever. Virology 257, 1-6 (1999).
54. Rothman AL. Dengue: defining protective versus pathologic immunity. J. Clin. Invest. 113, 946-951 (2004).
55. Mongkolsapaya J, Dejnirattisai W, Xu X et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nature Med. 9, 921-927 (2003).
56. Library DH, Endy TP, Houng HH et al. Differing influences of virus burden and immune activation on disease severity dengue-3 virus infections. J. Infect. Dis. 185, 1213-1221 (2002).
57. Vaughn DW, Green S, Kalayanarooj S et al. Dengue viremia titer, antibody response pattern and virus serotype correlate with disease severity. J. Infect. Dis. 181, 2-9 (2000).
58. Halstead SB, Rojanasuphot S, Sangkawibha N. Original antigenic sin in dengue. Am. J. Trop. Med. Hyg. 32, 154-156 (1983 ).
59. Malasit P. Complement and dengue hemorrhagic fever/dengue shock syndrome. SE Asian J. Trop. Med. Pub. Health 18, 316-320 (1987).
60. Avirutnan P, Malasit P, Seliger B, Bhakdi S, Husmann M. Dengue virus infection of human endothelial cells leads to chemokine production, complement activation and apoptosis. J. Immunol. 161, 6338-6346 (1998).
61. Rosen L. La pathogenese de la dengue hemorrhagique: discussion critique des hyptheses actuelles. Bull. Soc. Path. Ex. 79, 342-349 (1986).
62. Rosen L. Disease exacerbation caused by sequential dengue infections: myth or reality? Rev. Infect. Dis. 11, S840-S842 (1989).
63. Rosen L. Dengue in Greece in 1927 and the pathogenesis of dengue hemorrhagic fever: new data and a different conclusion. Am. J. Trop. Med. Hyg. 35, 642-653 (1986).
64. Sangkawibha N, Rojanasuphot S, Ahandrik S et al. Risk factors in dengue shock syndrome. A prospective epidemiologic study in Rayong, Thailand. Am. J. Epidemiol. 120, 653-669 (1984).
65. Graham RR, Juffrie M, Tan R et al. A prospective seroepidemiologic study on dengue in children 4 to 9 years of age in Yogyakarta, Indonesia I. Studies in 1995-1996. Am. J. Trop. Med. Hyg. 61, 412-419 (1999).
66. Kouri G, Guzman MG, Bravo JR, Triana C. Dengue hemorrhagic fever/dengue shock syndrome: lessons from the Cuban epdiemic, 1981. Bull. World Health Organ. 67, 375-380 (1989).
67. Guzman MG, Kouri G, Bravo J, Soler M, Vazquez S, Morier L. Dengue hemorrhagic fever in Cuba, 1981: a retrospective seroepidemiologic study. Am. J. Trop. Med. Hyg. 42, 179-184 (1990).
68. Bravo J, Guzman MG, Kouri GP. Why dengue hemorrhagic fever in Cuba. I. Individual risk factors for dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS). Trans. R. Soc. Trop. Med. Hyg. 81, 816-820 (1987).
69. Kouri G, Guzman MG, Bravo JR. Why dengue hemorrhagic fever in Cuba 2: an integral analysis. Trans. R. Soc. Trop. Med. Hyg. 81, 821-823 (1987).
70. Halstead SB. Pathophysiology and pathogenesis of dengue hemorrhagic fever. In: Monograph on Dengue/Dengue Hemorrhagic Fever Thongcharoen P (Ed.). World Health Organisation Regional Publication 22, 80-103 (1993).
71. Gonzalez D, Castro O, Kouri G et al. Classical dengue hemorrhagic fever from two dengue infections spaced 20 years or more apart. Havana, dengue 3 epidemic 2001-2002. Int. J. Infect. Dis. (2004) (In Press).
72. Valdes L, Guzman MG, Kouri G et al. La epidemiologia del dengue en Cuba en 1997. Rev. Panam. Salud. Pub. 6, 16-25 (1999).
73. Halstead SB, Streit TG, Lafontant JG et al. Haiti: absence of dengue hemorrhagic fever despite hyperendemic dengue virus transmission. Am. J. Trop. Med. Hyg. 65, 180-183 (2001).
74. De Fraites I, Smoak B, Trofa A et al. Dengue fever among US military personnel - Haiti, September to November, 1994. Morbid. Mortal. Wkly Rep. 4, 845-848 (1994).
75. Guzman MG, Kouri G, Bravo J, Valdes L, Vazquez S, Halstead SB. Effect of age on outcome of secondary dengue 2 infections. Int. J. Infect. Dis. 6, 118-124 (2002).
76. Rico-Hesse R, Boshell J, Mesa MTR et al. Origins of dengue Type 2 viruses associated with increased pathogenicity in the Americas. Virology 230, 244-251 (1997).
77. Lanciotti RS, Lewis JG, Gubler DJ, Trent DW. Molecular evolution and epidemiology on dengue 3 viruses. J. Gen. Virol. 75, 65-75 (1994).
78. Leitmeyer KC, Vaughn DW, Watts DM et al. Dengue virus strructural differences that correlate with pathogenesis. J. Virol. 73, 4738-4747 (1999).
79. Pryor MJ, Carr JM, Hocking H, Davidson AD, Li P, Wright PJ. Replication of dengue virus Type 2 in human monocyte-derived macrophages: comparisons of isolates and recombinant viruses with substitutions at amino acid 390 in the envelope glycoprotein. Am. J. Trop. Med. Hyg. 65, 427-434 (2001).
80. Cologna R, Rico-Hesse R. American genotype structures decrease dengue virus output from human monocytes and dendritic cells. J. Virol. 77, 3929-3928 (2003).
81. Kochel TJ, Watts DM, Halstead SB et al. Effect of dengue 1 antibodies on American dengue 2 infection and dengue hemorrhagic fever. Lancet 360(9329), 310-312 (2002).
82. Guzman MG, Deubel V. Pelegrino JL et al. Partial nucleotide and amino acid sequences of the envelope and the envelope/nonstructural protein-1 gene junction of four dengue-2 virus strains isolated during the 1981 Cuban epidemic. Am. J. Trop. Med. Hyg. 52, 241-246 (1995).
83. Sariol C, Pelegrino JL, Martine A, Arteaga E, Kouri G, Guzman MG. Detection and genetic relationhip in 17-year old paraffin embedded samples of Cuba. Am. J. Trop. Med. Hyg. 61, 994-1000 (1999).
84. Guzman MG, Kouri G, Valdes L et al. Epidemiological studies on dengue in Santiago de Cuba 1997. Am. J. Epidemiol. 152, 793-799 (2000).
85. Raut CG, Deolankar RE, Kolhapure RM, Goverdhan MK. Susceptibility of laboratory-bred rodents to the experimental infection with dengue virus Type 2. Acta Vriol. 40, 143-146 (1996).
86. Halstead SB, Shotwell H, Casals J. Studies on the pathogenesis of dengue infection in monkey. I. Clinical laboratory responses to primary infection. J. Infect. Dis. 128, 7-14 (1973).
87. Pugachev KV, Guirakhoo F, Trent DW, Monath TP. Traditional and novel approaches to flavivirus vaccines. Int. J. Parasitol. 33, 567-582 (2003).
88. Brandt W. Current approaches to the development of dengue vaccines and related aspects of the molecular biology of flaviviruses. J. Infect. Dis. 157, 1105-1111 (1988).
89. Eckels KH, Scott RM, Bancroft WH et al. Selection of attenuated dengue-4 viruses by serial passage in primary kidney cells. V. Human reponse to immunization with a candidate vaccine. Am. J. Trop. Med. Hyg. 33, 684-689 (1984).
90. Eckels E, Harrison VR, Summers PL, Russell PK. Dengue 2 vaccine preparation from a small plaque virus cline. Infect. Immun. 27, 175-180 (1980).
91. Edelman R, Ticket CO, Wasserman SS et al. A live attenuated dengue-1 vaccine candidate (45AZ5) passaged in primary dog kidney cell culture is attenuated and immunogenic for humans. J. Infect. Dis. 170, 1448-1455 (1994).
92. Bhamarapravati N, Yoksan S, Chayaniyayothin T, Angsubphakorn S, Bunyaratvej A. Immunization with a live attenuated dengue-2 virus candidate vaccine (16681-PDK 53): clinical, immunological and biological responses in adult volunteers. World Health Organization Bull. 65, 189-195 (1987).
93. Innis BL, Eckels KH, Kraiselburd E et al. Virulence of a live dengue virus vaccine candidate: a possible new marker of dengue virus attenuation. J. Infect. Dis. 158, 876-880 (1988).
94. Bhamarapravati N, Yoksan S. Study of bivalent dengue vaccine in volunteers. Lancet 1, 1077 (1989).
95. Bhamarapravati N, Yoksan S. Live attenuated tetravalent dengue vaccine. Vaccine (Suppl. 2), 44-47 (2000).
96. Vaughn DW, Hoke CH, Yoksan S et al. Testing a dengue 2 live attenuated vaccine (strain 16681 PDK 53) in the American volunteers. Vaccine 14, 329-336 (1996).
97. Khin MM, Jirakanjanakit N, Yoksan S, Bhamarapravati N. Infection, dissemination, transmission and biological attributes of dengue-2 PDK53 candidate vaccine virus after oral infection in Aedes aegypti. Am. J. Trop. Med. Hyg. 51, 864-869 (1994).
98. Jirakanjanakit N, Khin MM, Yoksan S, Bhamarapravati N. Dynamics of susceptibility and transmissibility of the live, attenuated candidate vaccines dengue-1 PDK13, Dengue-3PGMK30F3 and Dengue-4 PDK48 after oral infection in Aedes aegypti. Am. J. Trop. Med. Hyg. 61, 672-676 (1999).
99. Simmons JS, St John JH, Reynolds FHK. Experimental studies of dengue. In: Monographs of the Bureau of Science. Brown VH (Ed.). Manila Bureau of Printing, Manila, The Philippines Monograph 29, 1-489 (1931).
100. Putnak P, Cassidy K, Conforti N et al. Immunogenic and protective response in mice immunized with a purified inactivated dengue 2 virus vaccine prototype made in fetal thesus lung cells. Am. J. Trop. Med. Hyg. 55, 504-510 (1996).
101. Putnak R, Barvir DA, Burrous JM et al. Development of a purified, inactivated dengue 2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys. J. Infect. Dis. 174, 1176-1184 (1996).
102. Kaufman BM, Summers PL, Debois DR, Eckels KH. Monoclonal antibodies against dengue 2 E glycoprotein protect mice against lethal dengue infection. Am. J. Trop. Med. Hyg. 36, 427-434 (1987).
103. Kaufman BM, Summers PL, Dubois DR et al. Monoclonal antibodies for dengue virus prM glycoprotein protect mice against lethal dengue infection. Am. J. Trop. Med. Hyg. 41, 576-580 (1989).
104. Brandriss MW, Schelesinger JJ, Walsh EE, Briselli M. Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 virus. J. Gen. Virol. 67, 229-234 (1986).
105. Tan CHC, Yap EH, Singh M, Deubel V, Chan YC. Passive protection studies in mice with monoclonal antibodies directed against the nonstructural protein NS3 of dengue 1 virus. J. Gen. Virol. 71, 745-749 (1990).
106. Feighny R, Burrous J, McCown J, Hoke C, Putnak R. Purification of native dengue-2 viral proteins and the ability of purified proteins to protect mice. Am. J. Trop. Med. Hyg. 47, 405-412 (1992).
107. Zhang Y, Corver J, Chipman PR et al. Structures of immature flavivirus particles. Eur. Mol. Biol. Organ. J. 22, 2604-2613 (2003).
108. Allison SL, Schalich J, Stiasny K, Mandl CW, Heinz FX. Mutational evidence for an internal fusion peptide in flavivirus envelope protein E. J. Virol. 75, 4268-4275 (2001).
109. Beasley DM, Aaswkov JG. Epitopes on the dengue 1 virus envelope protein recognized by neutralizing IgM monoclonal antibodies. Virology 279, 447-458 (2001).
110. Roehrig JT. Immunochemistry of dengue viruses. In: Dengue and Dengue Hemorrhagic Fever. Gubler DJ, Kuno G (Eds). CAB International, London, UK, 199-219 (1997).
111. Vazquez S, Guzman MG, Guillen G et al. Immune response to synthetic peptides of dengue prM protein. Vaccine 20, 1823-1830 (2002).
112. Wengler G, Wengler G. An analysis of the antibody response against West Nile E protein purified by SDS-PAGE indicates that this protein does not contain sequential epitopes for efficient induction of neutralizing antibodies. J. Gen. Virol. 70, 987-992 (1989).
113. Allison SL, Stadler K, Mandl CW, Kunz C, Heinz FX. Synthesis and secretion of recombinant tick-borne encephalitis virus protein E in soluble and particulate form. J. Virol. 69, 5816-5820 (1995).
114. Rey FA, Heinz FX, Mandl C, Kunz C, Harrison SC. The envelope glycoprotein from tick-borne encephalitis virus at 2A resolution. Nature 375, 291-298 (1995).
115. Heinz FX, Stiasny K, Puschern-Auer G et al. Structural changes and functional control of the tick-borne encephalitis virus glycoprotein E by the heterodimeric association with protein prM. Virology 198, 109-117 (1994).
116. Lorenz IC, Allison SL, Heinz FX, Helenius A. Folding and dimerisation of tick-borne encephalitis virus envelope proteins prM and E in the endoplasmic reticulum. J. Virol. 76, 5480-5491 (2002).
117. Mackenzie JM, Jones MK, Young PR. Immunolocalization of the dengue virus nonstructural glycoprotein NS1 suggests a role in viral RNA replication. Virology 220, 232-240 (1996).
118. Jacobs MG, Robinson PJ, Bletchly C, Mackenzie JM, Young PR. Dengue virus nonstructural protein 1 is expressed in a glycosyl-phosphatidylinositol-linked form that is capable of signal transduction. Fed. Am. Soc. Exp. Biol. J. 14, 1603-1610 (2000).
119. Bartelma G, Padmanabhan R. Expression, purification and characterization of the RNA 5′-triphosphatase activity of dengue virus Type 2 nonstructural protein 3. Virology 299, 122-132 (2002 ).
120. Wu CF, Wang SH, Sun CM, Hu ST, Syu W. Activation of dengue protease autocleavage at the NS2B-NS3 junction by recombinant NS3 and GST-NS2B fusion proteins. J. Virol. Methods 114, 45-54 (2003).
121. Mathew A, Kurane I, Green S et al. Predominance of HLA-restricted cytotoxic T-lymphocyte responses to serotype-crossreactive epitopes on nonstructural proteins following natural secondary virus infection. J. Virol. 72, 3999-4004 (1998).
122. + cytotoxic T-lymphocyte clones crossreactive for dengue virus types 2, 3 and 4. Virology 240, 169-174 (1999).
123. Gould EA, Buckley A, Barret ADT, Cammack N. Neutralizing (54K) and non-neutralizing (54K and 48K) monoclonal antibodies against structural and nonstructural yellow fever virus proteins confer immunity in mice. J. Gen. Virol. 67, 591-595 (1986).
124. Falconar AKI. The dengue virus nonstructural 1 protein (NS1) generates antibodies to common epitopes on human blood clotting, integrin/adhesin proteins and binds to human endothelial cells: potential implications in hemorrhagic fever pathogenesis. Arch. Virol. 142, 897-916 (1997).
125. Starapoli I, Frenkiel MP, Megret F, Deubel V. Affinity-purified dengue-2 virus envelope glycoprotein induces neutralizing antibodies and protective immunity in mice. Vaccine 15, 1946-1954 (1997).
126. Bielefeldt-Ohmann H, Beasley DWC, Fitzpatrick DR, Aaskov JG. Analysis of a recombinant dengue-2 virus-dengue-3 hybrid envelope protein expressed in a secretory baculovirus system. J. Gen. Virol. 78, 2723-2733 (1997).
127. Srivastava AK, Putnak JR, Warren RL, Hoke CH. Mice immunized with a dengue Type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection. Vaccine 13, 1251-1258 (1995).
128. Smucny JJ, Kelly EP, Macarthy PO, King AD. Murine immunoglobulin G subclass responses following immunization with live dengue virus or a recombinant dengue envelope protein. Am. J. Trop. Med. Hyg. 53, 432-437 (1995).
129. Venugopal K, Gould EA. Towards a new generation of flavivirus vaccines. Vaccine 12, 966-974 (1994).
130. Delenda C, Starapoli I, Frenkiel MP, Cabanie L, Deubel V. Analysis of C-terminally truncated dengue 2 and dengue 3 virus envelope glyroproteins: processing in insect cells and immunogenic properties in mice. J. Gen. Virol. 75, 1569-1578 (1994).
131. Hahn YS, Lenches EM, Galler R, Rice CM, Dalrymple J, Strauss JH. Expression of the structural proteins of dengue 2 virus and yellow fever virus by recombinant vaccinia viruses. Arch. Virol. 115, 251-265 (1990).
132. Deubel V, Kinney RM, Esposito JJ et al. Dengue 2 virus envelope protein expressed by a recombinant vaccinia virus fails to protect monkeys against dengue. J. Gen. Virol. 69, 1921-1929 (1988).
133. Zhang YM, Hayes EP, McCarty TC et al. Immunization of mice with dengue structural proteins and nonstructural NS1 by baculovirus recombinant induces resistance to dengue virus encephalitis. J. Virol. 62, 3027-3031 (1988).
134. Schelesinger JJ, Brandriss MW, Walsh EE. Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus nonstructural glycoprotein NS1. J. Gen. Virol. 68, 853-857 (1987).
135. Delenda CH, Frenkiel MP, Deubel V. Protective efficacy in mice of a secreted form of recombinant dengue-2 virus envelope protein produced in baculovirus infected insect cells. Arch. Virol. 139, 197-207 (1994).
136. Feighny R, Burrons J, Putnak R. Dengue type-2 envelope protein made using recombinant baculovirus protects mice against challenge. Am. J. Trop. Med. Hyg. 50, 322-328 (1994).
137. Velzing J, Groen J, Drouet MT et al. Induction of protective immunity against dengue virus Type 2: comparison of candidate live attenuated and recombinant vaccines. Vaccine 17, 1312-1320 (1999).
138. Eckels KH, Dubois DR, Summers PL et al. Immunization of monkeys with baculovirus-dengue type-4 recombinants containing envelope and nonstructural proteins: evidence of priming and partial protection. Am. J. Trop. Med. Hyg. 50, 472-478 (1994).
139. Rice CM, Grakoui A, Galler R, Chambers TJ. Transcription of infectious yellow fever RNA full-length cDNA templates produced by in vitro ligation. New Biol. 1, 285-296 (1989).
140. Lai CJ, Zhao B, Hori H, Bray M. Infectious RNA transcribed from stably cloned full-length cDNA of dengue Type 4 virus. Proc. Natl Acad. Sci. USA 88, 5139-5143 (1991).
141. Chen W, Kawano H, Men R, Clark D, Lai CJ. Construction of intertypic chimeric dengue viruses exhibiting type 3 antigenicity and neurovirulence for mice. J. Virol. 69, 5186-5190 (1995).
142. Bray M, Lai CJ. Monkeys immunized with intertypic chimeric dengue viruses are protected against wild-type virus challenge. J. Virol. 70, 4162-4166 (1996).
143. Cahour A, Pletnev A, Vazeille-Falcoz M, Rosen L, Lai CJ. Growth-restricted dengue virus mutants containing deletions in the 5′ noncoding region of the RNA genome. Virology 207, 68-76 (1995).
144. Kinney RM, Butrapet S, Chang GJ et al. Construction of infectious cDNA clones for dengue 2 virus:strain 16681 and its attenuated vaccine derivative, strain PDK-53. Virology 230, 300-308 (1997).
145. Butrapet S, Huang CYH, Pierro DJ, Bhamarapravati N, Gubler DJ, Kinney RM. Attenuation markets of a candidate dengue Type 2 vaccine virus strain 16681 (PDK-53) are defined by mutations in the 5′ noncoding region and nonstructural proteins 1 and 3. J. Virol. 74, 3011-3019 (2000).
146. Kochel T, Wu SJ, Raviprakash K et al. Inoculation of plasmids expresing the dengue-2 envelope gene elicit neutralizing antibodies in mice. Vaccine 15, 547-552 (1997).
147. Porter KR, Kochel TJ, Raviprakash K, Phillips I, Hayes CG. Protective efficacy of a dengue 2 DNA vaccine in mice and the effect of CpG immunostimulatory motifs on antibody responses. Arch. Virol. 143, 997-1003 (1998).
148. Kanesa-Thasan N, Sun W, Kim-Ahn G et al. Safety and immunogeniticity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 19, 3179-3188 (2001).
149. Rothman AL, Kanesa-Thasan N, West K, Saluzzo JF, Ennis FA. Induction of lymphocyte responses to dengue virus by a candidate tetravalent live attenuated dengue vaccine. Vaccine 19, 4695-4699 (2001).
150. Sabchareon A, Lang J, Chanthavanich P et al. Safety and immunogenicity of tetravalent live attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio and multiple doses. Am. J. Trop. Med. Hyg. 66, 264-272 (2002).
151. Sabchareon A, Lang J, Yoksan S et al. Safety and immunogenicity of a three dose regimen of two tetravalent live attenuated dengue vaccines in 5- to 12-year-old Thai children. Pediatr. Infect. Dis. J. 23, 99-109 (2004).
152. Edelman R, Wasserman SS, Bodison SA et al. Phase I trial of 16 formulations of a tetravalent live attenuated dengue vaccine. Am. J. Trop. Med. Hyg. 69(Suppl. 6), 48-60 (2003).
153. Sun W, Edelman R, Kanesa-Thasan N et al. Vaccination of human volunteers with monovalent and tetravalent live attenuated dengue vaccine candidates. Am. J. Trop. Med. Hyg. 69(Suppl. 6), 24-31 (2003).
154. Chambers TJ, Nestorowicz A, Mason PW, Rice CM. Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties. J. Virol. 73, 3095-3101 (1999).
155. Guirakhoo F, Weltzin R, Chambers TJ et al. Recombinant chimeric yellow fever-dengue type 2 virus is immunigenic and protective in nonhuman primates. J. Virol. 74, 5477-5485 (2000).
156. Guirakhoo F, Arroyo J, Pugachev KV et al. Construction, safety and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J. Virol. 75, 7290-7304 (2001).
157. Guirakhoo F, Pugachev K, Zhang Z et al. Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J. Virol. 78, 4761-4775 (2004).
158. Huang CYH, Butrapet S, Pierro DJ et al. Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine. J. Virol. 74, 3020-3028 (2000).
159. Durbin AP, Karron RA. Sun W et al. Attenuation and immunogenicity in humans of a live dengue virus type-4 candidate with a 30 nucleotide deletion in its 3′-untranslated region. Am. J. Trop. Med. Hyg. 65, 405-413 (2001).
160. Troyer JM, Hanley KA, Whitehead SS et al. A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccines to mosquitoes. Am. J. Trop. Med. Hyg. 65, 414-419 (2001).
161. Blaney J, Johnson DH, Firestone CY, Hanson CT, Murphy BR, Whitehead SS. Chemical mutagenesis of dengue virus Type 4 yields mutant viruses which are temperature sensitive in vero cells or human liver cells and attenuated in mice. J. Virol. 75, 9731-9740 (2001).
162. Blaney JE, Johnson DH, Manipon GG et al. Generic basis of attenuation of dengue virus Type 4 small plaque mutants with restricted replication in suckling mice and mice transplanted with human liver cells. Vaccine 300, 125-139 (2002).
163. Whitehead SS, Hanley KA, Blaney JE, Gilmore LE, Elkins WR, Murphy BR. Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vacine candidates which are attenuated for mosquitoes, mice and rhesus monkeys. Vaccine 21, 4307-4316 (2003).
164. Whitehead SS, Falgout B, Hanley KA, Blaney JE, Markoff L, Murphy BR. A live attenuated dengue virus Type 1 vaccine candidate with a 30-nucleotide deletion in the 3′ untranslated region is highly attenuated and immunogenetic in monkeys. J. Virol. 77, 1653-1657 (2003).
165. Markoff L, Pang X, Houng HS et al. Derivation and characterization of a dengue Type 1 host range-restricted mutant virus that is attenuated and highly immunogenic in monkeys. J. Virol. 76, 3318-3328 (2002).
166. Kochel TJ, Raviptakash K, Hayes C et al. A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys. Vaccine 18, 3166-3173 (2000).
167. Raviprakash K, Kochel TJ, Ewing D et al. Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein. Vaccine 18, 2426-2434 (2000).
168. Raviprakash K, Porter KR, Kochel TJ et al. Dengue virus type 1 DNA vaccine induces protective immune responses in rhesus macaques. J. Gen. Virol. 81, 1659-1667 (2000).
169. Raviprakash K, Ewing D, Simmons M et al. Needle-free Biojector injection of a dengue virus type 1 DNA vaccine with human immunostimulatory sequences and the GM-CSF gene increases immunigenicity and protection from virus challenge in Aotus monkeys. Virology 315, 345-352 (2003).
170. Konishi E, Yamaoka M, Kurane I, Mason PW. A DNA vaccine expressing dengue type 2 premembrane and envelope genes induces neutralizing antibody and memory B-cells in mice. Vaccine 18, 1133-1139 (2000).
171. Konishi E, Fujii A. Dengue type 2 virus subviral extracellular particles produced by a stably transfected mammalian cell line and their evaluation for a subunit vaccine. Vaccine 20, 1058-1067 (2002).
172. Konishi E, Terazawa A, Imoto J. Simultaneous immunization with DNA and protein vaccines against Japanese encephalitis or dengue synergistically increases their own abilities to induce neutralizing antibody in mice. Vaccine 21, 1826-1832 (2003).
173. Simmons M, Murphy GS, Raviprakash K, Hayes CG. Characterization of antibody responses to combination of a dengue-2 DNA and dengue-2 recombinant subunit vaccine. Am. J. Trop. Med. Hyg. 65, 420-426 (2001).
174. Ocasionez R, Lopes da Fonseca BA. Recombinant plasmid expressing a truncated dengue-2 virus E protein without co-expression of prM protein induces partial protection in mice. Vaccine 19, 648-654 (2001).
175. Wu SF, Liao CL, Lin YL et al. Evaluation of protective efficacy and immune mechanisms of using a nonstructural protein NS1 in DNA vaccine against dengue 2 virus in mice. Vaccine 21, 3919-3929 (2003).
176. Simmons M, Nelson WM, Hayes CG. Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection mice. Am. J. Trop. Med. Hyg. 58, 655-662 (1998).
177. Simmons M, Murphy GS, Hayes CG. Short report: antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine. Am. J. Trop. Med. Hyg. 65, 159-161 (2001).
178. Jaiswal S, Khanna N, Swaminathan S. High level expression and one-step purification of recombinant dengue virus Type 2 envelope Domain III protein in Escherichia coli. Protein Expr. Purif. 33, 80-91 (2004).
179. Gonzalez G, Crombet T, Catala M et al. A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. Ann. Oncol 9, 431-435 (1998).
180. Perez A, Dickinson F, Cinza Z et al. Safety and preliminary immunogenicity of the recombinant outer membrane protein P64k of Neisseria meningitides in human volunteers. Biotechnol. Appl. Biochem. 34, 121-125 (2001).
181. Hermida L, Rodriguez R, Lazo L et al. A dengue-2 envelope fragment inserted within the structure of P64k meningococcal protein carrier enables a functional immune response against the virus in mice. J. Virol. Methods 115, 41-49 (2004).
182. Hermida L, Rodriguez R, Lazo L et al. A fragment of the envelope protein from dengue-1 virus, fused in two different sites of the meningococcal P64k protein carrier, induces a functional immune response in mice. Biotechnol. Appl. Biochem. 39, 107-114 (2004).
183. Kelly EP, Greene JJ, King AD, Innis BL. Purified dengue 2 virus envelope glycoprotein aggregates produced by baculovirus are immunogenic in mice. Vaccine 18, 2549-2559 (2000).
184. Mune M, Rodriguez R, Ramirez R et al. Carboxy terminally truncated dengue 4 virus envelope glycoprotein expressed in Pichia pastoris induce neutralizing antibodies and resistance to dengue 4 virus challenge in mice. Arch. Virol. 148, 2267-2273 (2003).
185. Guzman MG, Rodriguez R, Rodriguez-Roche R et al. Induction of neutralizing antibodies and partial protection from viral challenge in Macaca fascicularis immunized with recombinant dengue 4 envelope glycoprotein expresses in Pichia pastoris. Am. J Trop. Med Hyg. 69, 123-128 (2003).
186. Men R, Wyatt L, Tokimatsu I et al. Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue Type 2 virus induced resistance to dengue Type 2 virus challenge. Vaccine 18, 3113-3122 (2000).
187. Pang T. Vaccines for the prevention of neglected diseases - dengue fever. Curr. Opin. Biotechnol. 14, 332-336 (2003).
188. Kouri G, Guzman MG, Valdes L et al. Re-emergence of dengue in Cuba: a 1997 epidemic in Santiago de Cuba. Emerg. Infect. Dis. 1, 89-92 (1998).
189. Guzman MG, Kouri G, Valdes L, Bravo J, Vazquez S, Halstead SB. Enhanced severity of secondary dengue-2 infections:death rates in 1981 and 1997 Cuban outbreaks. Pan Am. J. Public Health 11, 223-227 (2002).
190. Watts DM, Porter KR, Putvatana P et al. Failure of secondary infection with American genotype dengue 2 to cause dengue hemorrhagic fever. Lancet 354, 1431-1433 (1999).
191. Holmes EC, Burch S. The causes and consequences of genetic variation in dengue virus. Trends Microbiol. 76, 74-77 (2000).
192. Holmes EC, Twiddy SS. The origin, emergence and evolutionary genetics of dengue virus. Infect. Genetics Evol. 3, 19-28 (2003).
193. Wang WK, Lin SR, Lee CM, King CC, Chang SC. Dengue type 3 virus in plasma is a population of closely related genomes:quasispecies. J. Virol. 76, 4662-4665 (2002).
194. Guzman MG, Kouri G, Vazquez S, Rosario D, Bravo J, Valdes L. DHF epidemics in Cuba, 1981 and 1997: some interesting observations. Dengue Bull. 23, 39-43 (1999).
195. Guzman MG, Kouri G, Halstead SB. Do escape mutants explain rapid increases in dengue case fatality rates within epidermics? Lancet 355, 1902-1903 (2000).
196. Lin CF, Lei HY, Liu CC et al. Generation of IgM antiplatelet autoantibody in dengue patient. J. Med Virol. 63, 143-149 (2001).
197. Lin CF, Shiau AL, Liu HS et al. Endothelial cell apoptosis induced by antibodies against dengue virus nonstructural protein 1 via production of nitric oxide. J. Immunol. 169, 657-664 (2002).
198. Chungue E, Poli L, Roche C, Gestas P, Glaziou P, Markoff LJ. Correlation between detection of plasminogen crossreactive antibodies and hemorrhage in dengue virus infection. J. Infect. Dis. 170, 1304-1307 (1994).